Intended Purpose:

  • Mental Cognition – Brain – Memory – Attention – Motivation – Productivity
  • Cerebral Blood Flow
  • Short-Term Memory

May also Support:

  • Menopause
  • Motion Sickness
  • Urinary Tract

Vinpocetine is a nootropic (from the Greek nous “mind” & trepein “turn”), a substance that improves mental function. It is an alkaloid derived from the flower of the lesser periwinkle (Vinca minor), indigenous in Europe but now a dense, ground-covering plant also found in North America. It is used as a drug in some European countries, prescribed to treat cerebrovascular disorders and age-related mental decline.

Safe and effective, it is a vasodilator, anticonvulsive and anti-inflammatory particular to the brain and central nervous system. Thus, unlike most substances, it is readily able to cross the blood-brain barrier where it has direct neural actions. Vinpocetine affects an enzyme (phosphodiesterase) and reduces calcium levels in the brain, both of which cause the smooth muscle that line blood vessels to constrict. Thus, it relaxes these muscles, allowing the vessels to open which increase blood flow and subsequent oxygen delivery.

With Aging, blood flow can gradually be diminished and Vinpocetine may be effective in alleviating associated cognitive function.   Clinical studies have shown that Vinpocetine is effective in promoting cerebrovascular health and climacteric effects in menopausal women, reducing the symptoms associated with hormonal changes.

However, a normal process in aging is the gradual restrictive carry capacity of blood thru the vascular system, whether it be the onset of atherosclerosis or even “spider veins” often found in legs. Therefore, Vinpocetine can act to restore normal function and blood flow.

Importantly and the reason Vinpocetine was included in this formulation, in healthy individuals, it has been clinically proven to improve cognitive function – memory, attention, motivation and productivity.

(1) Brush J, Mendenhall E, Guggenheim A et al: The effect of Echinacea purpurea, Astragalus membranaceus and Glycyrrhiza glabra on CD69 expression and immune cell activation in humans. Phytother Res. 2006 Aug;20(8):687-95. http://www.ncbi.nlm.nih.gov/pubmed/16807880.

(2) Jovanović ZB, Pavlović AM, Pekmezović T et al: Transcranial Doppler assessment of cerebral vasomotor reactivity in evaluating the effects of vinpocetine in cerebral small vessel disease: a pilot study. Ideggyogy Sz. 2013 Jul 30;66(7-8):263-8. http://www.ncbi.nlm.nih.gov/pubmed/23971358

(3) Skoromets AA, Aliev KT, Lalayan TV et al: Cognitive functions and treatment of their impairment in elderly patients with the vertebrobasilar insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(4):18-24. (Russian). http://www.ncbi.nlm.nih.gov/pubmed/23739435

(4) Tabeeva GR, Azimova IuE: The multimodal strategy for the neuroprotection in stroke: results of the Russian multicenter clinical-epidemiological program SOKOL. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(12 Pt 2):20-30. (Russian). http://www.ncbi.nlm.nih.gov/pubmed/23388602

(5) Valikovics A, Csányi A, Németh L: Study of the effects of vinpocetin on cognitive functions. Ideggyogy Sz. 2012 Mar 30;65(3-4):115-20. (Hungarian). http://www.ncbi.nlm.nih.gov/pubmed/23136730

(6) Chukanova EI; Efficacy of cavinton in the treatment of patients with chronic blood flow insufficiency. Russian multicenter clinical-epidemiological program “CALIPSO”. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(12):49-52. (Russian). http://www.ncbi.nlm.nih.gov/pubmed/21311488

(7) Gavrilova SI, Kolykhalov IV, Fedorova IaB et al: Possibilities of preventive treatment of Alzheimer’s disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(1):62-9. (Russian). http://www.ncbi.nlm.nih.gov/pubmed/20436440

(8) Afon’kin VIu, Dobretsov KG, Sipkin AV: The new scheme of cavinton application to the treatment of chronic neurosensory loss of hearing. Vestn Otorinolaringol. 2009; (6):69-70. (Russian). http://www.ncbi.nlm.nih.gov/pubmed/20081798

(9) Skoromets AA, Tanashian MM, Chukanova EI et al: A multicenter program on assessment of efficacy and safety of a new therapeutic scheme for patients with chronic cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(5 Suppl 2):44-8. (Russian). http://www.ncbi.nlm.nih.gov/pubmed/19894300

(10) Chukanova EI: Cavinton in the complex treatment of patients with chronic cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(9):35-9. (Russian). http://www.ncbi.nlm.nih.gov/pubmed/19770831

(11) Feher G, Koltai K, Kesmarky G et al: Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine. 2009 Mar;16(2-3):111-7. http://www.ncbi.nlm.nih.gov/pubmed/19135345

(12) Valikovics A: Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz. 2007 Jul 30;60(7-8):301-10. (Hungarian). http://www.ncbi.nlm.nih.gov/pubmed/17713111

(13) Kemény V, Molnár S, Andrejkovics M et al: Acute and chronic effects of vinpocetine on cerebral hemodynamics and neuropsychological performance in multi-infarct patients. J Clin Pharmacol. 2005 Sep;45(9):1048-54. http://www.ncbi.nlm.nih.gov/pubmed/16100299

(14) Szilágyi G, Nagy Z, Balkay L et al: Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study.J Neurol Sci. 2005 Mar 15;229-230:275-84. http://www.ncbi.nlm.nih.gov/pubmed/15760651

(15) Vas A, Christer H, Sóvágó J et al: Human positron emission tomography with oral 11C-vinpocetine]. Orv Hetil. 2003 Nov 16;144(46):2271-6. (Hungarian). http://www.ncbi.nlm.nih.gov/pubmed/14702922

(16) Szapáry L, Horváth B, Alexy T et al: Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease. Orv Hetil. 2003 May 18;144(20):973-8. (Hungarian). http://www.ncbi.nlm.nih.gov/pubmed/12830727

(17) Gulyás B, Halldin C, Sandell J et al: PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects. Acta Neurol Scand. 2002 Dec;106(6):325-32. http://www.ncbi.nlm.nih.gov/pubmed/12460136

(18) Gulyás B, Halldin C, Sóvágó J et al: Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine. Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1031-8. http://www.ncbi.nlm.nih.gov/pubmed/12173017

(19) Bönöczk P, Panczel G, Nagy Z: Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. Eur J Ultrasound. 2002 Jun;15(1-2):85-91. http://www.ncbi.nlm.nih.gov/pubmed/12044859

(20) Kolarov G, Orbetsova M, Nalbanski B et al: Complex effects of cavinton on climacteric symptoms. Akush Ginekol (Sofiia). 2001;42(2):37-41. (Bulgarian). http://www.ncbi.nlm.nih.gov/pubmed/11799757

(21) Feigin VL, Doronin BM, Popova TF et al: Vinpocetine treatment in acute ischaemic stroke: a pilot single- blind randomized clinical trial. Eur J Neurol. 2001 Jan;8(1):81-5. http://www.ncbi.nlm.nih.gov/pubmed/11509086

(22) Truss MC, Stief CG, Uckert S et al: Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol. 2000 Dec;18(6):439-43. http://www.ncbi.nlm.nih.gov/pubmed/11204266

(23) Miyazaki M: The effect of a cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiology. 1995 Jan;46(1):53-8. http://www.ncbi.nlm.nih.gov/pubmed/7818157

(24) Hindmarch I, Fuchs HH, Erzigkeit H: Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991 Spring;6(1):31-43. http://www.ncbi.nlm.nih.gov/pubmed/2071888

(25) Dutov AA, Gal’tvanitsa GA, Volkova VA et al: Cavinton in the prevention of the convulsive syndrome in children after birth injury. Zh Nevropatol Psikhiatr Im S S Korsakova. 1991;91(8):21-2. (Russian). http://www.ncbi.nlm.nih.gov/pubmed/1661506

(26) Kiss E: Adjuvant effect of cavinton in the treatment of climacteric symptoms. Ther Hung. 1990;38(4):170-3. http://www.ncbi.nlm.nih.gov/pubmed/2094056

(27) Bhatti JZ, Hindmarch I: Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol. 1987 Oct;2(4):325-31. http://www.ncbi.nlm.nih.gov/pubmed/3693872

(28) Balestreri R, Fontana L, Astengo F: A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction.J Am Geriatr Soc. 1987 May;35(5):425-30. http://www.ncbi.nlm.nih.gov/pubmed/3553281

(29) Pilgramm M, Schumann K: Need for rheologically active, vasoactive and metabolically active substances in the initial treatment of acute acoustic trauma. HNO. 1986 Oct;34(10):424-8. (German). http://www.ncbi.nlm.nih.gov/pubmed/2432041

(30) Domzał T, Kozłowski P, Zaleska : Cavinton in the treatment of ischemic cerebral stroke. Clinical and computerized-tomographic evaluation. Neurol Neurochir Pol. 1986 May-Jun;20(3):234-40. (Polish). http://www.ncbi.nlm.nih.gov/pubmed/3537828

(31) Subhan Z, Hindmarch I: Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur J Clin Pharmacol. 1985;28(5):567-71. http://www.ncbi.nlm.nih.gov/pubmed/3899677

(32) Bodo D, Kotovskaia AR, Galle RR et al: Effectiveness of the preparation Gavinton in preventing motion sickness. Kosm Biol Aviakosm Med. 1982 May-Jun;16(3):49-51. (Russian). http://www.ncbi.nlm.nih.gov/pubmed/7098411